BLCM Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

HOUSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2019 Healthcare Conference on Tuesday, June 4 at 2:00 p.m. EDT in New York City.

A live webcast of the presentation may be accessed from the section of the Bellicum website. An archived version of the webcast will be available for replay immediately following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic T cell therapies. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. Bellicum’s rivo-cel product candidate is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. More information can be found at .

Contacts:

Investors

Robert H. Uhl

Managing Director

Westwicke IR

858-356-5932

Media

Jim Heins

Senior Vice President

Westwicke PR

203-682-8251

EN
29/05/2019

Underlying

BLCMBellicum Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bellicum Pharmaceuticals Inc

 PRESS RELEASE
Free
BLCM Bellicum Pharma...

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Str...

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most rec...

March 14, 2023 1 EN
 PRESS RELEASE
Free
BLCM Bellicum Pharma...

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer...

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Ph...

February 16, 2023 1 EN
 PRESS RELEASE
Free
BLCM Bellicum Pharma...

CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing ...

CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 20,000 stock options. The Compen...

January 31, 2023 1 EN
 PRESS RELEASE
Free
BLCM Bellicum Pharma...

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordan...

January 31, 2023 1 EN
 PRESS RELEASE
Free
BLCM Bellicum Pharma...

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 ...

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held...

January 19, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch